The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Umang Vohra, the company's CEO, confirmed Abraxane's launch in the second half of FY26, which will be manufactured at Cipla’s Goa facility following its recent regulatory approval. Meanwhile ...

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

and the US business aiding Cipla to register growth in FY26. “The US business should witness a gradual recovery from 1QFY26F, with the Lanreotide franchise’s supplies resuming. With the USFDA’s ...

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net profit, reaching Rs 1,571 crore, compared to Rs 1,056 crore in the same period last year. The profit after ...

Shares of drugmaker Cipla Ltd. surged to the day's high, gaining as much as 4% after the company's December quarter results. The results were a beat across parameters.

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.